VasoStitch Completes Successful In Vivo Study of Its Breakthrough Access-and-Closure System for Nonsurgical Deployment of Transcatheter Therapies
The challenge with percutaneous catheter-based cardiac procedures is that a surgical cut-down is required for access and then closure. VasoStitch has developed two platform technologies designed to access and close percutaneous therapy sites without the need for open surgery, thus making catheter-based interventions simpler and more accessible.
"Current surgical means of arterial or cardiac access and closure for large diameter catheter-based interventions adds about an hour to an already long and complex procedure. A device that can replicate the current â€˜gold standard of surgical access and repair in a more rapid and facile fashion will reduce healthcare costs dramatically, enhance adoption of large-diameter cardiovascular and endovascular therapies, and improve the efficiency of patient management," said David W. J. Smith, President and CEO of VasoStitch. "We now look forward to our First-in-Human milestone."
VasoStitch was founded by Amir Belson, MD. Dr. Belson previously founded NeoGuide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009; more recently, Dr. Belson also has founded Emboline, Vascular Pathways and ZipLine Medical.
VasoStitch is an emerging medical device company that is developing nonsurgical transfemoral and transapical access-and-closure systems to facilitate deployment of large-diameter transcatheter therapeutic devices-designed to reduce procedural complexity and eliminate the need for an "open" surgical procedure.
Posted by Sean Fenske, Editor-in-Chief, MDT